Sugi Predict

Sugi Predict / Compounds / SCHEMBL1689371

SCHEMBL1689371

SCHEMBL1689371

O=C(O)C1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 20/20 0.80
▸ TNKS O95271 1/20 0.80
▸ ADORA1 P30542 1/20 0.80
▸ CDK6 Q00534 1/20 0.80
▸ PDE3A Q14432 1/20 0.80
▸ PARP6 Q2NL67 1/20 0.80
▸ PARP15 Q460N3 1/20 0.80
▸ PARP14 Q460N5 1/20 0.80
▸ PARP10 Q53GL7 1/20 0.80
▸ TIPARP Q7Z3E1 1/20 0.80
▸ PARP8 Q8N3A8 1/20 0.80
▸ PARP16 Q8N5Y8 1/20 0.80
▸ PARP12 Q9H0J9 1/20 0.80
▸ TNKS2 Q9H2K2 1/20 0.80
▸ PARP11 Q9NR21 1/20 0.80
▸ PARP2 Q9UGN5 1/20 0.80
▸ PARP4 Q9UKK3 1/20 0.80
▸ PARP3 Q9Y6F1 1/20 0.80
▸ PRAP1 Q96NZ9 1/20 0.77
▸ HDAC1 Q13547 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27015363 0.92 PARP1 (0.80) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL78306 0.91 PARP1 (0.80) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL19569971 0.90 PARP1 (0.90) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL25150398 0.90 PARP1 (0.79) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL30364626 0.90 PARP1 (0.79) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL30332603 0.89 PARP1 (0.79) PARP1TNKSADORA1CDK6PDE3A
Olaparib SCHEMBL29352148 0.89 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
Olaparib SCHEMBL426568 0.89 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
Olaparib SCHEMBL29392087 0.89 PARP1 (1.00) PARP1TNKSADORA1CDK6PDE3A
SCHEMBL27776285 0.89 PARP1 (0.87) PARP1TNKSADORA1CDK6PDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 — — US disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 — — US disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 — — US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 — — US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 — — US disclosed
US-10449192-B2 Phthalazinone derivatives KUDO PHARMACEUTICALS LIMITED (GB) 2019-10-22 — — US disclosed
US-10449192-B2 Phthalazinone derivatives KUDO PHARMACEUTICALS LIMITED (GB) 2019-10-22 — — US disclosed
US-20180185363-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2018-07-05 — — US disclosed
US-20180185363-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2018-07-05 — — US disclosed
US-20180185363-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2018-07-05 — — US disclosed
US-7449464-B2 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient KUDOS PHARMACEUTICALS LIMITED (GB) 2008-11-11 — — US disclosed
US-7449464-B2 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient KUDOS PHARMACEUTICALS LIMITED (GB) 2008-11-11 — — US disclosed
US-20080200469-A1 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis KUDOS PHARMACEUTICALS LIMITED 2008-08-21 — — US disclosed
US-20080200469-A1 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis KUDOS PHARMACEUTICALS LIMITED 2008-08-21 — — US disclosed
US-20080200469-A1 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis KUDOS PHARMACEUTICALS LIMITED 2008-08-21 — — US disclosed
US-20060149059-A1 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2006-07-06 — — US disclosed
CN-1788000-A Phthalazinone derivatives KUDOS PHARM LTD (GB) 2006-06-14 — — CN disclosed
EP-1633724-A1 PHTHALAZINONE DERIVATIVES Kudos Pharmaceuticals Limited (GB) 2006-03-15 — — EP disclosed
US-20050059663-A1 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2005-03-17 — — US disclosed
WO-2004080976-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2004-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059663-A1 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 PARP1 3029/4885TNKS 4048/4885ADORA1 1343/4885
US-10449192-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 PARP1 3029/4885TNKS 4048/4885ADORA1 1343/4885
US-11160803-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 PARP1 3029/4885TNKS 4048/4885ADORA1 1343/4885
US-20080200469-A1 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis PARP1, PARP11, PARP2 PARP1 1/4885TNKS 139/4885ADORA1 1799/4885
US-20060149059-A1 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 PARP1 3176/4885TNKS 4111/4885ADORA1 1177/4885
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 PARP1 2/4885TNKS 40/4885ADORA1 2511/4885
US-20230015617-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 PARP1 3176/4885TNKS 4111/4885ADORA1 1177/4885
US-20180185363-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 PARP1 3029/4885TNKS 4048/4885ADORA1 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.